Moolec Science (MLECW) Research & Development (2022 - 2024)
Moolec Science (MLECW) posted Research & Development of -$298003.0 for Q4 2024, up 29.97% sequentially from -$425542.0 in Q3 2024, and up 42.25% YoY from -$209492.5 in Q1 2024.
Moolec Science (MLECW) Research & Development (2022 - 2024) Analysis & Trends
Moolec Science has reported Research & Development for 3 years, with the latest figure at -$298003.0 in Q4 2024.
- Quarterly Research & Development rose 42.25% year-over-year to -$298003.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.6 million (up 13.97% YoY) and the FY2024 annual result came in at -$1.8 million, down 31.16% from the prior year.
- Research & Development improved to -$298003.0 in Q4 2024 per MLECW's latest filing, from -$425542.0 in the prior quarter.
- Over five years, Research & Development peaked at $176161.0 in Q1 2022 and troughed at -$1.7 million in Q2 2022.
- A 3-year average of -$447020.3 and a median of -$404315.5 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 78.11% in 2023, down 1535.21% in 2023.
- Over 3 years, Research & Development stood at -$31557.0 in 2022, then tumbled by 1535.21% to -$516022.0 in 2023, then jumped by 42.25% to -$298003.0 in 2024.
- According to Business Quant data, Research & Development over the past three periods registered -$298003.0, -$425542.0, and -$420895.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -298,003.00 |
| Sep 30, 2024 | -425,542.00 |
| Jun 30, 2024 | -420,895.00 |
| Mar 31, 2024 | -447,621.00 |
| Dec 31, 2023 | -516,022.00 |
| Sep 30, 2023 | -387,736.00 |
| Jun 30, 2023 | -370,632.00 |
| Mar 31, 2023 | -576,096.00 |
| Dec 31, 2022 | -31,557.00 |
| Sep 30, 2022 | -372,932.00 |
| Jun 30, 2022 | -1.69 Mn |
| Mar 31, 2022 | 176,161.00 |